Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiora Pharmaceuticals (KPRX) Total Current Liabilities (2016 - 2025)

Kiora Pharmaceuticals (KPRX) has disclosed Total Current Liabilities for 11 consecutive years, with $2.6 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Total Current Liabilities changed N/A year-over-year to $2.6 million, compared with a TTM value of $2.6 million through Sep 2025, changed N/A, and an annual FY2024 reading of $6.0 million, up 267.73% over the prior year.
  • Total Current Liabilities was $2.6 million for Q3 2025 at Kiora Pharmaceuticals, down from $6.0 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $6.0 million in Q4 2024 and bottomed at $1.4 million in Q1 2021.
  • Average Total Current Liabilities over 5 years is $2.3 million, with a median of $2.0 million recorded in 2021.
  • The sharpest move saw Total Current Liabilities plummeted 34.08% in 2023, then soared 267.73% in 2024.
  • Year by year, Total Current Liabilities stood at $1.6 million in 2021, then surged by 86.03% to $3.0 million in 2022, then tumbled by 45.43% to $1.6 million in 2023, then skyrocketed by 267.73% to $6.0 million in 2024, then crashed by 57.06% to $2.6 million in 2025.
  • Business Quant data shows Total Current Liabilities for KPRX at $2.6 million in Q3 2025, $6.0 million in Q4 2024, and $1.6 million in Q1 2024.